Loading...
Please wait, while we are loading the content...
Similar Documents
Fecal microbiota transplantation ameliorates active ulcerative colitis.
| Content Provider | Europe PMC |
|---|---|
| Author | Chen, Hui-Ting Huang, Hong-Li Xu, Hao-Ming Luo, Qing-Ling He, Jie Li, Yong-Qiang Zhou, You-Lian Nie, Yu-Qiang Zhou, Yong-Jian |
| Copyright Year | 2020 |
| Abstract | Ulcerative colitis (UC) is a complex chronic pathological condition of the gut in which microbiota targeted treatment, such as fecal microbiota transplantation (FMT), has shown an encouraging effect. The aim of the present study was to investigate the efficacy and safety of FMT in patients with mild or moderate UC. A single-center, open-label study was designed, including 47 patients with mild or moderate active UC who received three treatments of fresh FMT via colonic transendoscopic enteral tubing within 1 week. The inflammatory bowel disease questionnaire, partial Mayo scores, colonoscopy, erythrocyte sedimentation rate, C-reactive protein level and procalcitoin values were used to assess the efficacy of FMT and alteration in gut microbiota was detected by 16S ribosomal RNA-sequencing. Before FMT, microbiota Faecalibacterium prausnitzii (F. prausnitzii) levels were significantly decreased in patients with UC compared with healthy donors (P<0.01). At 4 weeks post-FMT, F. prausnitzii levels were significantly increased (P<0.05), and the Mayo score was significantly decreased (1.91±1.07 at baseline vs. 4.02±1.47 at week 4; P<0.001) in patients with UC compared with healthy donors. Steroid-free clinical responses were reported in 37 patients (84.1%), and steroid-free clinical remission was achieved in 31 patients (70.5%) at week 4 post-FMT, however, steroid-free remission was not achieved in any patient. No adverse events were reported in 41 (93.2%) patients after FMT or during the 12-week follow-up. Shannon's diversity index and Chao1 estimator were also improved in patients with UC receiving FMT. In conclusion, the results of the present study suggested that FMT resulted in clinical remission in patients with mild to moderate UC, and that the remission may be associated with significant alterations to the intestinal microbiota of patients with UC. Furthermore, F. prausnitzii may serve as a diagnostic and therapeutic biomarker for the use of FMT in UC. |
| ISSN | 17920981 |
| Journal | Experimental and Therapeutic Medicine |
| Volume Number | 19 |
| PubMed Central reference number | PMC7086197 |
| Issue Number | 4 |
| PubMed reference number | 32256746 |
| e-ISSN | 17921015 |
| DOI | 10.3892/etm.2020.8512 |
| Language | English |
| Publisher | D.A. Spandidos |
| Publisher Date | 2020-02-11 |
| Access Restriction | Open |
| Rights License | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Copyright: © Chen et al. |
| Subject Keyword | fecal microbiota transplantation ulcerative colitis gut microbiota colonoscopy Faecalibacterium prausnitzii |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology and Microbiology Cancer Research |
